TSTickerStarGet alerts

BIAF 10-Q filed 2026-11-06 | Key takeaways

BIAF filed its 10-Q; the most relevant disclosure change is unchanged Going concern assessment: Management concludes substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance date given $2.6M cash on hand and expected operating expenditures.

Share this story

Key takeaways

  • CyPath Lung test volume increased 37% year-over-year to 526 tests in Q3 2026, but revenue declined 8% to $273K due to lower average reimbursement per test

  • Going concern: Company had $2.6M cash at September 30, 2026 and projects sufficient cash only through March 2027 without additional financing

  • Warrant reclassification: $6.4M warrant liability was recorded and subsequently reclassified to equity following the August 2026 private placement; $1.2M loss on warrant liabilities recognized

  • Stock split: 1-for-15 reverse stock split completed August 21, 2026; shares outstanding reduced from 451,852 (June 30) to 1,166,625 (September 30) on post-split basis

  • Subsequent financing: October 2026 closed $4M registered direct offering with 116,545 shares and pre-funded warrants exercisable for 536,836 shares

  • Clinical trial: 11 clinical sites activated for CyPath Lung longitudinal trial including 9 VA/military medical centers

  • Operating expenses increased 23% to $4.6M in Q3 2026 driven by 75% increase in clinical development costs and 25% increase in SG&A

Key metrics

Net revenue - Q3 2026Q3 2026
$1,070,280-26%
Net revenue - 9M 2026Nine months 2026
$3,932,386-14%
Net loss - Q3 2026Q3 2026
($5,277,023)+4.5%
Net loss - 9M 2026Nine months 2026
($12,273,715)+4.3%
Cash and cash equivalentsSeptember 30, 2026
$2,550,034
CyPath Lung revenue - Q3 2026Q3 2026
$273,000-8%
CyPath Lung revenue - 9M 2026Nine months 2026
$1.1 million+79%
Operating loss - Q3 2026Q3 2026
($3,510,672)+53%

Disclosure changes

  • Going concern assessment

    Management concludes substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance date given $2.6M cash on hand and expected operating expenditures.

    The company projects sufficient cash only through March 2027 without additional financing, requiring continued capital raises.
  • Warrant liability reclassification

    The company recorded a $6.4M warrant liability for liability-classified warrants issued in the August 2026 private placement, then reclassified to equity after certain terms resulted in conversion to equity classification; $1.2M loss on warrant liabilities recognized.

    Warrant reclassification impacts equity and non-operating expense; $1.2M loss recognized in Q3 2026.
  • Reverse stock split

    1-for-15 reverse stock split completed August 21, 2026; all share and per-share amounts retroactively adjusted.

    Share count significantly reduced; affects per-share metrics and outstanding shares.
  • Operating lease right-of-use asset

    Operating lease right-of-use asset increased to $730,572 at September 30, 2026 from $334,289 at December 31, 2025, due to new research laboratory lease entered in June 2026 and out-of-period adjustment for April 2024 lease amendment.

    Operating lease liability increased proportionally; reflects expanded facility footprint.
  • Revenue concentration

    Patient service fees (CyPath Lung and anatomical pathology) represent the majority of revenue; CyPath Lung direct billing was $273K in Q3 2026 (26% of revenue).

    CyPath Lung revenue growing year-over-year but average reimbursement declining.
  • Subsequent events - October 2026 financing

    In October 2026, company raised $4M through issuance of 116,545 common shares and 536,836 pre-funded warrants (all exercised at closing) plus unregistered warrants to purchase 980,072 shares at $6.122 exercise price.

    Post-period financing extends cash runway; increases shares outstanding significantly.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow BIAF in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert